The National Institutes of Health has launched a clinical trial testing whether a monoclonal antibody, dupilumab, can reduce asthma attacks and improve lung function and asthma symptoms in children with poorly controlled allergic asthma who live in low-income urban neighborhoods.
The American Lung Association millennial lung study will track 4,000 young adults (aged 25-35) at the age of peak lung health for five years to evaluate how their environment, lifestyle, and physical activity habits affect respiratory health.
Administering a 10 ug dose of the Pfizer/BioNTech COVID-19 vaccine in children age 5-11 was safe and effective, according to a Phase 2/3 trial.
Novavax Inc’s COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
Read More
An NIH Phase 1/2 clinical trial will study fully-vaccinated adult volunteers who will receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens.
Read More
A clinical trial of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma, compared to placebo.
Read More
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
Read More
A Phase 3 trial of AstraZeneca/Amgen’s Tezepelumab found the drug had a clinically meaningful 77% reduction in annualized asthma exacerbation rates in patients with severe asthma.
Read More
NIH will conduct a clinical trial to test the antibiotic dalbavancin for safety and efficacy in treating complicated Staphylococcus aureus (S. aureus) bacteremia.
Read More
A Phase I/II clinical trial in the Netherlands will test AKS-452, a COVID-19 vaccine candidate that is shelf-stable for at least 4 months without refrigeration.
Read More
A Phase 3 clinical trial will explore a pool of up to seven drugs approved by FDA for other conditions – an approach called drug repurposing – and test their safety and effectiveness in treating mild to moderate COVID-19.
Read More
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
Read More
Regen-CoV — a monoclonal antibody cocktail from Regeneron — reduced the risk of symptomatic SARS-CoV-2 infections by 81% in a Phase 3 clinical trial.
Read More
Updated Phase 3 data analyzing the Pfizer-BioNTech COVID-19 vaccine up to six months after second vaccination showed it was 91.3% effective overall and 100% effective versus severe disease.
Read More
Results of a Phase 3 trial of Pfizer/BioNTech’s COVID-19 vaccine demonstrated a 100% efficacy and robust antibody responses in participants aged 12-15 years old, according to the company.
Read More